Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
2.022
+0.022 (1.10%)
May 19, 2025, 11:06 AM - Market open
Company Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom.
Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial.
The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Cyclacel Pharmaceuticals, Inc.
| Country | Malaysia |
| Founded | 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Sing Wong |
Contact Details
Address: Tower 11, Level 10, Avenue 5, No. 8 Kuala Lumpur, 59200 Malaysia | |
| Phone | 60 9 08517 7330 |
| Website | cyclacel.com |
Stock Details
| Ticker Symbol | CYCC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001130166 |
| CUSIP Number | 23254L603 |
| ISIN Number | US23254L8019 |
| Employer ID | 91-1766850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sing Ee Wong | Chairman, Chief Executive Officer and President |
| Cu Seng Kiu | Executive Director, Chief Financial Officer and Secretary |
| Gill Christie | Director of Human Resources |
| Grace Kim | Investor Relations Executive |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | PRE 14C | Filing |
| May 7, 2025 | 8-K | Current Report |
| May 6, 2025 | 8-K | Current Report |
| May 1, 2025 | 424B3 | Prospectus |
| Apr 29, 2025 | EFFECT | Notice of Effectiveness |
| Apr 25, 2025 | 8-K | Current Report |
| Apr 25, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |